Crinetics Pharmaceuticals Inc (CRNX) is 18.59% away from 50-day simple Moving Average despite all headwinds

As on Wednesday, Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) got off with the flyer as it spiked 3.52% to $47.62, before settling in for the price of $46.00 at the close. Taking a more long-term approach, CRNX posted a 52-week range of $15.50-$47.62.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 64.83%. Meanwhile, its Annual Earning per share during the time was -10.59%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 13.21%. This publicly-traded company’s shares outstanding now amounts to $77.93 million, simultaneously with a float of $71.18 million. The organization now has a market capitalization sitting at $3.71 billion. At the time of writing, stock’s 50-day Moving Average stood at $40.37, while the 200-day Moving Average is $29.72.

Crinetics Pharmaceuticals Inc (CRNX) Ownership Facts and Figures

Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Crinetics Pharmaceuticals Inc’s current insider ownership accounts for 8.67%, in contrast to 89.34% institutional ownership. According to the most recent insider trade that took place on Mar 28 ’24, this organization’s Director sold 17,500 shares at the rate of 46.38, making the entire transaction reach 811,650 in total value, affecting insider ownership by 6,000. Preceding that transaction, on Mar 22 ’24, Company’s Chief Operating Officer sold 32,359 for 44.31, making the whole transaction’s value amount to 1,433,675. This particular insider is now the holder of 52,580 in total.

Crinetics Pharmaceuticals Inc (CRNX) Earnings and Revenue Records

If we go through the results of last quarter, which was made public on 12/30/2023, the company posted -$0.9 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -$0.86) by -$0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.8 per share during the current fiscal year.

Crinetics Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 13.21% and is forecasted to reach -3.54 in the upcoming year.

Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Trading Performance Indicators

Let’s observe the current performance indicators for Crinetics Pharmaceuticals Inc (CRNX). It’s Quick Ratio in the last reported quarter now stands at 13.07. The Stock has managed to achieve an average true range (ATR) of 2.54.

In the same vein, CRNX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.70, a figure that is expected to reach -0.81 in the next quarter, and analysts are predicting that it will be -3.54 at the market close of one year from today.

Technical Analysis of Crinetics Pharmaceuticals Inc (CRNX)

Through scrutinizing the latest numbers posted by the [Crinetics Pharmaceuticals Inc, CRNX], it can be observed that its last 5-days Average volume of 1.4 million was better the volume of 0.8 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 81.75% While, its Average True Range was 2.59.

Raw Stochastic average of Crinetics Pharmaceuticals Inc (CRNX) in the period of the previous 100 days is set at 97.72%, which indicates a major rise in contrast to 95.23% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 83.43% that was higher than 55.89% volatility it exhibited in the past 100-days period.